{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-24-000024","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.280402+00:00","generated_at":"2026-06-04T23:07:52.611811+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board","bullets":["Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.","Skye Drynan appointed as Class III director; former Capital Group Partner and Senior BioPharma Analyst.","Each new director receives $40,000 annual cash retainer and option for 230,000 shares vesting over three years.","Dr. Nathan's guidance intended to support expansion of seralutinib clinical program into PH-ILD."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-24-000024","json":"https://secwatch.observer/filing/0001728117-24-000024.json","markdown":"https://secwatch.observer/filing/0001728117-24-000024.md","text":"https://secwatch.observer/filing/0001728117-24-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/0001728117-24-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/goss-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:07:52.611811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5549fae9c6","claim":"Steven Nathan was appointed as Class I director at Gossamer Bio, Inc..","evidence_excerpt":"Steven Nathan, M.D. to serve as a Class I director effective March 11, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/0001728117-24-000024-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"},{"claim_id":"97e2e9f53e","claim":"Skye Drynan was appointed as Class III director at Gossamer Bio, Inc..","evidence_excerpt":"appointed Skye Drynan to serve as a Class III director effective March 11, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/0001728117-24-000024-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}